Mycoplasma genitalium (M.genitalium, or Mgen) is a pathogen that is increasingly associated with cervicitis, pelvic inflammatory disease, preterm labor, spontaneous abortion, and infertility. Although many are asymptomatic, M.genitalium can be found in 10-30% of women with symptoms/exam findings of cervicitis.
NAAT testing for M.genitalium is FDA-approved for use with urine and urethral, penile meatal, endocervical, and vaginal swab samples.
According to CDC guidelines, women with recurrent or persistent cervicitis should be tested for M.genitalium, and testing should be considered among women with PID. It is not recommended to test for asymptomatic infections at this time, even in pregnancy.
High rates of macrolide resistance in this pathogen make 1 g of Azithromycin insufficient. The recommended regimen for NAAT-positive M.genitalium infections is: Doxycycline 100 mg PO BID x 7 days to reduce bacterial load, followed by moxifloxacin 400 mg PO daily x 7 days.
Overall, more studies are needed to truly determine the clinical relevance of this pathogen.
Consider testing for M.genitalium in patients presenting with recurrent or persistent cervicitis or pelvic inflammatory disease, as this may not respond to typical antibiotic regimens.
Hufstetler, K., Llata, E., Miele, K., & Quilter, L. A. S. (2024). Clinical Updates in Sexually Transmitted Infections, 2024. Journal of women's health (2002), 33(6), 827–837. https://doi.org/10.1089/jwh.2024.0367
